Pro Medicus Financials
PME Stock | 230.00 2.36 1.04% |
Operating Margin 0.7307 | PE Ratio 292.8333 | Profit Margin 0.5127 | Payout Ratio 1.1604 | EPS Estimate Current Year 0.76 |
Pro | Select Account or Indicator |
Understanding current and past Pro Medicus Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Pro Medicus' financial statements are interrelated, with each one affecting the others. For example, an increase in Pro Medicus' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Pro Medicus' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pro Medicus. Check Pro Medicus' Beneish M Score to see the likelihood of Pro Medicus' management manipulating its earnings.
Pro Medicus Stock Summary
Pro Medicus competes with Westpac Banking, Champion Iron, Ridley, Peel Mining, and Perpetual Credit. Pro Medicus is entity of Australia. It is traded as Stock on AU exchange.Foreign Associate | USA |
Specialization | Health Care, Health Care Equipment & Services |
Instrument | Australia Stock View All |
Exchange | Australian Securities Exchange |
ISIN | AU000000PME8 |
Business Address | 450 Swan Street, |
Sector | Health Care Technology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.promed.com.au |
Phone | 61 3 9429 8800 |
You should never invest in Pro Medicus without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Pro Stock, because this is throwing your money away. Analyzing the key information contained in Pro Medicus' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Pro Medicus Key Financial Ratios
Pro Medicus' financial ratios allow both analysts and investors to convert raw data from Pro Medicus' financial statements into concise, actionable information that can be used to evaluate the performance of Pro Medicus over time and compare it to other companies across industries.Revenue | 161.5 M | ||||
Gross Profit | 126.79 M | ||||
EBITDA | 120.76 M | ||||
Net Income | 82.79 M | ||||
Total Asset | 257.43 M |
Pro Medicus Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 95.6M | 125.6M | 157.1M | 202.1M | 257.4M | 270.3M | |
Other Current Liab | 4.1M | 5.6M | 8.2M | 10.0M | 12.8M | 13.5M | |
Net Debt | (41.1M) | (39.4M) | (61.4M) | (89.4M) | (58.0M) | (55.1M) | |
Retained Earnings | 49.6M | 66.9M | 92.6M | 127.1M | 173.4M | 182.0M | |
Accounts Payable | 835K | 872K | 1.6M | 1.0M | 1.7M | 1.8M | |
Cash | 43.4M | 42.0M | 63.7M | 91.2M | 60.1M | 63.1M | |
Net Receivables | 17.0M | 24.4M | 27.4M | 40.7M | 49.2M | 51.7M | |
Inventory | 35K | 34K | 77K | 55K | 49K | 75.3K | |
Total Liab | 35.5M | 43.9M | 55.3M | 63.4M | 69.7M | 73.2M | |
Total Current Assets | 61.5M | 87.6M | 119.8M | 163.8M | 206.6M | 216.9M | |
Short Term Debt | 522K | 574K | 604K | 1.4M | 553K | 525.4K | |
Other Liab | 21.0M | 24.2M | 26.8M | 31.3M | 36.0M | 37.8M | |
Other Assets | 9.4M | 13.2M | 40.5M | 1.0 | 12.4M | 0.95 | |
Other Current Assets | 1.0M | 1.3M | 1.8M | 1.6M | 1.9M | 950.4K | |
Intangible Assets | 18.8M | 20.0M | 22.3M | 21.3M | 20.1M | 10.2M | |
Net Tangible Assets | 41.3M | 61.7M | 79.4M | 117.4M | 135.0M | 141.8M | |
Long Term Debt Total | 1.8M | 2.0M | 1.7M | 1.2M | 1.4M | 1.0M | |
Net Invested Capital | 60.2M | 81.7M | 101.7M | 138.8M | 187.7M | 96.2M | |
Net Working Capital | 48.8M | 69.9M | 93.0M | 132.9M | 172.0M | 180.6M |
Pro Medicus Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 5K | 538K | 649K | 386K | 347.4K | 687.2K | |
Operating Income | 30.1M | 42.4M | 62.4M | 83.9M | 112.2M | 117.8M | |
Ebit | 30.1M | 42.9M | 63.1M | 86.1M | 112.3M | 117.9M | |
Ebitda | 37.7M | 50.1M | 70.4M | 94.1M | 120.8M | 126.8M | |
Income Before Tax | 30.0M | 42.9M | 63.1M | 86.1M | 116.5M | 122.3M | |
Net Income | 23.1M | 30.9M | 44.4M | 60.6M | 82.8M | 86.9M | |
Income Tax Expense | 6.9M | 12.0M | 18.6M | 25.5M | 33.7M | 35.4M | |
Total Revenue | 56.8M | 67.9M | 93.5M | 124.9M | 161.5M | 169.6M | |
Cost Of Revenue | 20.9M | 21.2M | 23.2M | 32.5M | 39.2M | 41.2M | |
Gross Profit | 35.9M | 46.7M | 70.3M | 92.4M | 122.3M | 128.4M | |
Research Development | 6.8M | 6.4M | 6.5M | 7.1M | 8.2M | 8.6M | |
Tax Provision | 6.9M | 12.0M | 18.6M | 25.5M | 33.7M | 35.4M | |
Net Interest Income | 172K | 180K | 649K | 2.4M | 4.8M | 5.1M | |
Interest Income | 172K | 180K | 649K | 2.4M | 4.8M | 5.1M |
Pro Medicus Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 11.1M | (1.4M) | 21.6M | 27.6M | (31.2M) | (29.6M) | |
Free Cash Flow | 23.5M | 31.1M | 52.6M | 56.1M | 80.1M | 84.1M | |
Other Non Cash Items | 7.5M | 7.2M | 16.3M | 1.1M | 86.7M | 91.1M | |
Capital Expenditures | 7.9M | 7.7M | 9.0M | 6.4M | 6.7M | 7.0M | |
Net Income | 23.1M | 30.9M | 44.4M | 60.6M | 82.8M | 86.9M | |
End Period Cash Flow | 43.4M | 42.0M | 63.7M | 91.2M | 60.1M | 63.1M | |
Change To Inventory | (4K) | 1K | (43K) | 22K | 6K | 6.3K | |
Dividends Paid | 10.9M | 13.5M | 18.8M | 26.1M | 36.6M | 38.4M | |
Depreciation | 845K | 803K | 813K | 834K | 8.5M | 8.9M | |
Change To Netincome | 3.6M | 2.1M | 395K | (240K) | (276K) | (262.2K) | |
Investments | (7.7M) | (19.7M) | (8.5M) | (7.6M) | (73.3M) | (69.6M) |
Pro Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pro Medicus's current stock value. Our valuation model uses many indicators to compare Pro Medicus value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pro Medicus competition to find correlations between indicators driving Pro Medicus's intrinsic value. More Info.Pro Medicus is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.60 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Pro Medicus is roughly 1.65 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pro Medicus' earnings, one of the primary drivers of an investment's value.Pro Medicus Systematic Risk
Pro Medicus' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pro Medicus volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was four with a total number of output elements of fifty-seven. The Beta measures systematic risk based on how returns on Pro Medicus correlated with the market. If Beta is less than 0 Pro Medicus generally moves in the opposite direction as compared to the market. If Pro Medicus Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pro Medicus is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pro Medicus is generally in the same direction as the market. If Beta > 1 Pro Medicus moves generally in the same direction as, but more than the movement of the benchmark.
Pro Medicus Total Assets Over Time
Pro Medicus November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Pro Medicus help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Pro Medicus. We use our internally-developed statistical techniques to arrive at the intrinsic value of Pro Medicus based on widely used predictive technical indicators. In general, we focus on analyzing Pro Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pro Medicus's daily price indicators and compare them against related drivers.
Downside Deviation | 1.89 | |||
Information Ratio | 0.3234 | |||
Maximum Drawdown | 8.73 | |||
Value At Risk | (2.38) | |||
Potential Upside | 3.32 |
Additional Tools for Pro Stock Analysis
When running Pro Medicus' price analysis, check to measure Pro Medicus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pro Medicus is operating at the current time. Most of Pro Medicus' value examination focuses on studying past and present price action to predict the probability of Pro Medicus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pro Medicus' price. Additionally, you may evaluate how the addition of Pro Medicus to your portfolios can decrease your overall portfolio volatility.